Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alireza Atri

Showing results (61-70 of 143) with videos related to

Pageof 15
Sort By:
Neuro-Degenerative Diseases|August 16, 2006
Prevalence and effects of lobar microhemorrhages in early-stage dementiaAlireza Atri, Joseph J Locascio, Jenny M Lin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersMarisa N Denkinger, Alpana Singh, James Liu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 11, 2021
Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care ProgramDanielle Goldfarb, Angela M Allen, Lori E Nisson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 12, 2026
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's diseasePhilip Scheltens, Alireza Atri, Howard H Feldman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2023
Expectations and clinical meaningfulness of randomized controlled trialsRonald C Petersen, Paul S Aisen, J Scott Andrews, et al.
Journal of Alzheimer'S Disease : JAD|July 1, 2019
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for StakeholdersYoussef H El-Hayek, Ryan E Wiley, Charles P Khoury, et al.
Lancet (London, England)|March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Journal of Clinical and Experimental Neuropsychology|February 9, 2022
An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson's DiseaseRoShunna Lea, Jared F Benge, Charles H Adler, et al.
Alzheimer Disease and Associated Disorders|May 18, 2010
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkersAlberto Serrano-Pozo, Gloria L Vega, Dieter Lütjohann, et al.
Parkinsonism & Related Disorders|September 5, 2024
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohortAlexander Choi, Nan Zhang, Charles H Adler, et al.
Pageof 15

Showing results (61-70 of 143) with videos related to

Sort By:
Pageof 15
Neuro-Degenerative Diseases|August 16, 2006
Prevalence and effects of lobar microhemorrhages in early-stage dementiaAlireza Atri, Joseph J Locascio, Jenny M Lin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersMarisa N Denkinger, Alpana Singh, James Liu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 11, 2021
Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care ProgramDanielle Goldfarb, Angela M Allen, Lori E Nisson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 12, 2026
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's diseasePhilip Scheltens, Alireza Atri, Howard H Feldman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2023
Expectations and clinical meaningfulness of randomized controlled trialsRonald C Petersen, Paul S Aisen, J Scott Andrews, et al.
Journal of Alzheimer'S Disease : JAD|July 1, 2019
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for StakeholdersYoussef H El-Hayek, Ryan E Wiley, Charles P Khoury, et al.
Lancet (London, England)|March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Journal of Clinical and Experimental Neuropsychology|February 9, 2022
An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson's DiseaseRoShunna Lea, Jared F Benge, Charles H Adler, et al.
Alzheimer Disease and Associated Disorders|May 18, 2010
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkersAlberto Serrano-Pozo, Gloria L Vega, Dieter Lütjohann, et al.
Parkinsonism & Related Disorders|September 5, 2024
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohortAlexander Choi, Nan Zhang, Charles H Adler, et al.
Pageof 15